Adolescent With Psychosis, Daily 'Spice' Use, and a Positive THC Immunoassay
A 16-year-old is brought to an adolescent clinic by parents after an episode of agitation, paranoia, and 'seeing shadows' at school. He admits using 'spice' daily for 3 months, sometimes with alcohol, and denies other drugs. He takes atomoxetine 40 mg daily for ADHD and has no prior psychosis. Urine immunoassay is positive for cannabinoids (THC) at a 50 ng/mL cutoff; the laboratory does not test for synthetic cannabinoids. He reports tolerance, using more than intended, and continued use despite school suspension. He has lost 4 kg, sleeps 4 hours nightly, and has a resting heart rate of 104/min. Blood pressure is 138/84; temperature 37.4°C. Physical exam shows conjunctival injection and dry mucous membranes. No focal neurologic deficits. His parents ask whether the positive drug test 'proves' he used marijuana and whether he needs inpatient detox.
1. Interpret the urine drug screen and explain its limitations for this patient's reported substance.
Read the worked answer
A positive immunoassay for cannabinoids detects metabolites of delta-9-tetrahydrocannabinol and related compounds, but it is a screening test. Synthetic cannabinoids such as 'spice' are structurally distinct and are usually not detected by routine THC immunoassays, so a positive result neither proves nor excludes synthetic cannabinoid use. The result could reflect prior cannabis use, a cross-reacting substance, or a false positive. Confirmatory testing with liquid chromatography-tandem mass spectrometry is needed, and synthetic cannabinoids require a specific panel.
Clinically, do not let the immunoassay result override the history. The reported daily 'spice' use, tolerance, and continued use despite consequences are more informative than the screening test. Explain to the parents that a positive screen is a clue, not a diagnosis, and that the absence of a synthetic cannabinoid result is a limitation of the test ordered.
2. Using DSM-5, what diagnosis is supported, and what differential must be excluded?
Read the worked answer
The history supports a moderate to severe cannabis-type use disorder: tolerance, using more than intended, continued use despite school suspension, and likely craving or withdrawal. DSM-5 does not have a separate synthetic cannabinoid use disorder; the cannabis use disorder criteria are commonly applied, with documentation that the substance is a synthetic cannabinoid.
The differential includes stimulant intoxication, primary psychotic disorder, delirium, and alcohol withdrawal. His tachycardia, agitation, and paranoia could reflect synthetic cannabinoid intoxication, but persistent psychosis after 24–48 hours of abstinence would require psychiatric evaluation. ADHD and atomoxetine do not explain new visual hallucinations. Weight loss and poor sleep suggest a broader substance-related and social problem, not simply 'experimentation.'
3. What immediate management and level of care is indicated?
Read the worked answer
He does not automatically need inpatient detox. Assess safety, hydration, and whether psychosis persists after a period of observation. If he is agitated, use behavioral measures first and short-term benzodiazepines with caution; antipsychotics may be needed for severe agitation but can lower the seizure threshold and should not substitute for assessment. Treat dehydration and monitor vital signs.
Arrange a follow-up visit within 72 hours, confirmatory testing, and a family meeting. Recommend outpatient substance use treatment with adolescent-specific services, and screen for depression, trauma, and school supports. Inpatient or emergency psychiatric evaluation is indicated if paranoia, hallucinations, or suicidal ideation persist or if he cannot be safely monitored at home.